Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

O. Hataji



Author of

  • +

    P3.10 - Poster Session 3 - Chemotherapy (ID 210)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P3.10-022 - Efficacy and safety of bevacizumab-based therapy in advanced non-squamous non small cell lung cancer : A retrospective study. (ID 1431)

      09:30 - 09:30  |  Author(s): O. Hataji

      • Abstract

      Background
      Bevacizumab (BEV) improves clinical response in patients with advanced NSCLC when it is used in combination with platinum-based chemotherapy. This study assesses the efficacy of bevacizumab as a maintenance therapy.

      Methods
      We retrospectively reviewed 67 patients with NS-NSCLC that were treated with bevacizumab (15mg/kg) in combination with any standard chemotherapy at Matsusaka Municipal Hospital (Japan) from November, 2009 through December, 2011. The therapy with bevacizumab was continued till the occurrence of disease progression or unacceptable toxicity; 45 patients received bevacizumab as a maintenance therapy. Survival was evaluated using the Kaplan-Meier curve.

      Results
      The median overall survival was 24.9 months, progression free survival was 7.0 months, and the overall response rate was 70.5%. No significant differences in overall survival or progression survival were found among regimens in which bevacizumab was used. As a maintenance therapy, the median progression survival was 6.0 months in the bevacizumab alone group and 9.9 months in the bevacizumab plus pemetrexed group (P=0.012). Grade 3/4 adverse events included neutropenia (44.8%), thrombopenia (9.0%), hypertension (14.9%), anorexia (4.5%), hepatopathy (4.5%), and nephropathy (3.0%). One patient had tracheoesophageal fistula.

      Conclusion
      The efficacy of regimens in which bevacizumab was included was similar. The combined therapy of bevacizumab plus pemetrexed as a maintenance therapy significantly improved the overall progression free survival compared to therapy with bevacizumab alone.